CStone’s CS2009 trispecific antibody reinforces three clinical validations at ESMO
With data from over 300 patients across multiple tumor types and Phase 3 trials coming soon, the evidence supports CS2009’s mechanism, safety and antitumor efficacy Key Takeaways: CS2009 delivered strong…
PODCAST: Japanese Auto Cuts, and a Drugmaker’s Fall
By Doug Young & Rene Vanguestaine Nissan and Honda weigh major cuts of up to 30% in their China car production. What's driving the trend, and is it likely to…
CHINA BULLETIN: Bring on the Equipment Upgrades, Says Beijing
In this week’s issue spying cranes, a TikTok sale and a meaty IPO. On a scale of 1 to 100, we give the week a 60 for offshore-listed China stocks.…
FAST NEWS: CStone drug approved for treatment of advanced non-small cell lung cancer
The Latest: Drug maker CStone Pharmaceuticals (2616.HK) announced on Tuesday its Pralsetinib, also known by the brand name Gavreto, was approved by China’s drug regulator as a first-line treatment for…
FAST NEWS: Drug companies say they’re unaffected by Silicon Valley Bank failure
The latest: Several Hong Kong-listed pharmaceutical companies disclosed that they have deposits at U.S.-based Silicon Valley Bank (SVB), which was taken over by the Federal Deposit Insurance Corp. (FDIC) last…
CStone’s Commercialization Capacity Put to Test With Latest Drug Approval
Company’s four drug approvals in a year will contribute major revenue, but will also challenge CStone’s ability to commercialize its products Key takeaways: Its rollout of four new drugs will…
CStone Revs Up for Big Growth With New Drug Approval
Company says China has approved its latest cancer drug, which it is commercializing with global pharmaceutical giant Pfizer Key takeaways: CStone announced its monoclonal antibody drug Cejemly has been approved…
Recent Articles
RELATED ARTICLES
-
Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
688506.SHG - AI in China’s medical aesthetics sector: From non-core services to clinical device integration
- Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
-
Akeso’s overseas drug promise fails to slow share decline
9926.HK
-
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
2617.HK
- Precision-drug maker Impact Therapeutics ignites IPO frenzy
-
Alphamab seals $2.2 billion licensing deal with AI biotech
9966.HK
